Resistance is futile with fourth-generation EGFR inhibitors Editorial

  

Authors:	Marasco, M.; Misale, S.
Title:	Resistance is futile with fourth-generation EGFR inhibitors
Keywords:	epidermal growth factor; human cell; overall survival; exon; genetics; mutation; erlotinib; monotherapy; note; progression free survival; apoptosis; pharmacodynamics; carcinoma, non-small-cell lung; lung neoplasms; epidermal growth factor receptor; cetuximab; protein tyrosine kinase inhibitor; lung tumor; xenograft; gefitinib; tumor cell; binding site; dimerization; therapy resistance; mammalian target of rapamycin inhibitor; ligand binding; egfr protein, human; pharmacology; epidermal growth factor receptor kinase inhibitor; scatter factor receptor; non small cell lung cancer; neu differentiation factor; clinical outcome; egfr signaling; erbb receptors; afatinib; dacomitinib; humans; human; osimertinib
Journal Title:	Nature Cancer
Volume:	3
Issue:	4
ISSN:	2662-1347
Publisher:	Nature Research
Date Published:	2022-04-01
Start Page:	381
End Page:	383
Language:	English
DOI:	10.1038/s43018-022-00365-2
PUBMED:	35422504
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128940616&doi=10.1038%2fs43018-022-00365-2&partnerID=40&md5=3cfc0596b6170fef9e856a54e4c5011b
Notes:	Note -- Export Date: 1 June 2022 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/194762